Blood biomarker panels can be used in the field of Alzheimer’s disease (AD) as an early screening tool for subjects at risk for being affected by amyloidopathy in their brains.

Future blood biomarker panels for AD will likely consist of the ratio of ß-amyloid(Aß)(1-42)/Aß(1-40), combined with proteins which reflect other pathological processes of Alzheimer’s disease (AD).

In this review, several gaps are identified for implementation of blood biomarker panels in clinical routine or clinical trials, including more stringent acceptance criteria for validation, better standard operating procedures for collection, storage, and testing of biological samples, as well as more stringent selection criteria and characterization of antibodies for inclusion in the assay design.

Analytical validation and biological/clinical validation need to be combined to ultimately arrive at tests with optimal clinical value for a specific context-of-use.